Caveolin-1 suppresses tumor formation through the inhibition of the unfolded protein response
Author
dc.contributor.author
Díaz, María I.
Author
dc.contributor.author
Díaz, Paula
Author
dc.contributor.author
Castillo Bennett, Jimena
Author
dc.contributor.author
Urra, Hery
Author
dc.contributor.author
Ortiz, Rina
Author
dc.contributor.author
Contreras Orellana, Pamela
Author
dc.contributor.author
Hetz Flores, Claudio
Author
dc.contributor.author
Quest, Andrew F. G.
Admission date
dc.date.accessioned
2021-03-15T20:55:45Z
Available date
dc.date.available
2021-03-15T20:55:45Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Cell Death and Disease (2020) 11:648
es_ES
Identifier
dc.identifier.other
10.1038/s41419-020-02792-4
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/178695
Abstract
dc.description.abstract
Caveolin-1 (CAV1), is a broadly expressed, membrane-associated scaffolding protein that acts both, as a tumor suppressor and a promoter of metastasis, depending on the type of cancer and stage. CAV1 is downregulated in human tumors, tumor cell lines and oncogene-transformed cells. The tumor suppressor activity of CAV1 is generally associated with its presence at the plasma membrane, where it participates, together with cavins, in the formation of caveolae and also has been suggested to interact with and inhibit a wide variety of proteins through interactions mediated by the scaffolding domain. However, a pool of CAV1 is also located at the endoplasmic reticulum (ER), modulating the secretory pathway in a manner dependent on serine-80 (S80) phosphorylation. In melanoma cells, CAV1 expression suppresses tumor formation, but the protein is largely absent from the plasma membrane and does not form caveolae. Perturbations to the function of the ER are emerging as a central driver of cancer, highlighting the activation of the unfolded protein response (UPR), a central pathway involved in stress mitigation. Here we provide evidence indicating that the expression of CAV1 represses the activation of the UPR in vitro and in solid tumors, reflected in the attenuation of PERK and IRE1 alpha signaling. These effects correlated with increased susceptibility of cells to ER stress and hypoxia. Interestingly, the tumor suppressor activity of CAV1 was abrogated by site-directed mutagenesis of S80, correlating with a reduced ability to repress the UPR. We conclude that the tumor suppression by CAV1 involves the attenuation of the UPR, and identified S80 as essential in this context. This suggests that intracellular CAV1 regulates cancer through alternative signaling outputs.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1090071
1130250
1170925
11180825
ICGEB Project
CRP/CH108-03
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDAP
15010006
15130011
Fondecyt post-doctoral award
3140446
3170140
ANIDFONDAP
15150012
Office of Naval Research
N62909-16-12003
Takeda Pharmaceutical Company Ltd
P09-015-F
FONDEF
ID16I10223
D11E1007
United States Department of Defense
Air Force Office of Scientific Research (AFOSR)
FA9550-16-1-0384
CONICYT-Brazil
441921/2016-7
Muscular Dystrophy Association
Conicyt PhD student fellowships